Form 4: Janux Therapeutics Executive Granted Equity Awards

Janux Therapeutics' Chief Corporate and Business Development Officer, Janeen Noel Doyle, received significant equity grants, including restricted stock units and stock options.

Summary

• Janeen Noel Doyle, Chief Corporate and Business Development Officer of Janux Therapeutics, Inc. (JANX), reported new equity grants.
• On January 2, 2026, Doyle was granted 36,000 Restricted Stock Units (RSUs) of common stock at a price of $0 per unit.
• These RSUs represent a contingent right to receive one share of common stock each and will vest in four equal annual installments beginning on January 1, 2027.
• Following this transaction, Doyle beneficially owns 80,000 shares of common stock directly.
• Additionally, on January 2, 2026, Doyle was granted stock options to purchase 126,000 shares of common stock with an exercise price of $13.65 per share.
• 25% of the shares subject to the option will vest on January 1, 2027, with the remaining balance vesting in equal monthly installments over a three-year period thereafter.
• The stock options have an expiration date of January 1, 2036.
• Following this transaction, Doyle beneficially owns 126,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The filing reports routine executive equity grants, which are generally positive for aligning management incentives with shareholder interests. It does not contain any negative news or unexpected events.

Positives

• The equity grants align the interests of a key executive, Janeen Noel Doyle, with those of shareholders, incentivizing long-term performance.
• The grants represent a significant component of executive compensation, indicating the company's commitment to retaining and motivating its leadership.

Future Outlook

NA

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. These grants are designed to align management's long-term interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The equity grants aim to align the interests of a key executive with shareholders, potentially leading to better long-term performance.
• Employees (Executive): Janeen Noel Doyle receives significant compensation through these grants, which serves as an incentive for continued service and performance.

Next Steps

• Vesting of 25% of stock options on January 1, 2027, with the balance vesting monthly over three years.
• First annual vesting installment of Restricted Stock Units (RSUs) on January 1, 2027, with subsequent installments annually thereafter.

Key Dates

Keywords

Janux Therapeutics, JANX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Janeen Noel Doyle